However, further research is needed to determine whether the loss of ATRX is associated with epigenetic landscape reprogramming, as well as increased levels of telomerase reverse transcriptase (TERT) and alternative lengthening of telomeres (ALT) expression, in glioma subtypes [19, 20]. The gene discussed is TERT; the disease is central nervous system cancer.